AstraZeneca rises 2% on pact with Reliance subsidiary
AstraZeneca Pharma India shares rose 2% to ₹6,154 on November 17 after signing a Letter of Intent with Reliance subsidiary Strand Life Sciences. The companies will explore healthcare collaboration opportunities, including improving cancer diagnosis. AstraZeneca's Q2 FY27 revenue grew 30.4% to ₹729.1 crore, while profit rose 15% to ₹62.33 crore.
read more at Finology


